More CD34+ stem cells.
Better survival rates.

Compared to cord blood banking alone, Placenta-Cord banking yields 39% more of a particular type of cell called a CD34+ stem cell.¹ Studies have shown that using more CD34+ stem cells can lead to a significant survival advantage in transplant patients.^2,3

Effect of Cells on Survival

"Data from: Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618."

These findings are from a study of 102 patients at the University of Minnesota School of Medicine and Cancer Center (a comprehensive cancer center recognized by the National Cancer Institute).

"Thanks to LifebankUSA®, we became knowledgeable and confident that we were doing the right thing [for] our daughter's healthy future. It is a relief knowing our daughter's stem cells are in the hands of such a competent group of professionals."

-Peg B.
LifebankUSA client
Texas

Cord blood and placenta-derived stem cells banked with LifebankUSA are indicated for hematopoietic reconstitution (the reformation of blood cellular components) for autologous use or use in first or second degree blood relatives. Any use of cord blood and placental stem cells other than for hematopoietic reconstitution is considered investigational, including regenerative medicine* therapies.

The chance that a child will use his/her own stored stem cells during his/her lifetime for currently treated conditions is estimated at 1 in 400 (J.J. Nietfeld). These odds may increase if there is a family history of certain blood disorders or cancers. The potential risks and benefits of stem cell transplantation vary and depend on many factors, such as the amount and quality of the stem cells collected, the HLA compatibility between recipient and donor, and the client’s overall health. Talk with your health care provider. For more information, call us at 1-877-LIFEBANKUSA (1-877-543-3226) or visit www.lifebankusa.com. View Product Information.

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.

References:

Data on file A, LifebankUSA; 2010.
Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618.
Styczynski J, Cheung Y-K, Garvin J, et al. Unrelated donor transplants: outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004;34(2):129-136.
Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.